Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "MEA"

1567 News Found

Enlivex reports promising six-month data for Allocetra in knee osteoarthritis
Clinical Trials | November 27, 2025

Enlivex reports promising six-month data for Allocetra in knee osteoarthritis

Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide


Otsuka files FDA application for first-in-class ADHD drug
Clinical Trials | November 27, 2025

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor


Novartis scores FDA nod for game-changing SMA treatment
Biotech | November 26, 2025

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA


Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub
R&D | November 25, 2025

Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub

The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre


Eli Lilly to unveil major breast cancer data at SABCS 2025
Clinical Trials | November 25, 2025

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival


Thermo Fisher opens two new centers in Hyderabad
Biotech | November 25, 2025

Thermo Fisher opens two new centers in Hyderabad

The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing


Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials
Clinical Trials | November 25, 2025

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years


Abbott to acquire Exact Sciences for $21 billion
News | November 25, 2025

Abbott to acquire Exact Sciences for $21 billion

Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology


GE HealthCare to acquire Intelerad for $2.3 billion, expanding cloud and AI imaging footprint
Healthcare | November 25, 2025

GE HealthCare to acquire Intelerad for $2.3 billion, expanding cloud and AI imaging footprint

The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market